Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2026

This “Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Respiratory Syncytial Virus (RSV): Understanding

Respiratory Syncytial Virus (RSV): Overview

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory virus that primarily infects the upper and lower respiratory tract, including the nose, throat, and lungs. It belongs to the paramyxovirus family and is one of the most common causes of respiratory illness worldwide, especially in infants, young children, older adults, and immunocompromised individuals. Transmission occurs through respiratory droplets generated by coughing or sneezing, direct contact with infected individuals, or touching contaminated surfaces followed by contact with the eyes, nose, or mouth.

RSV infections typically occur seasonally and are a major cause of bronchiolitis and pneumonia in young children.

The symptoms of RSV usually appear within 4-6 days after exposure and initially resemble mild upper respiratory tract infections. Common symptoms include runny nose, cough, sneezing, fever, wheezing, and reduced appetite. In infants, symptoms may also include irritability, poor feeding, and breathing difficulties. In more severe cases, particularly among high-risk populations, RSV can lead to serious conditions such as bronchiolitis and pneumonia, characterized by rapid breathing, chest retractions, wheezing, and cyanosis.

The pathophysiology involves infection of respiratory epithelial cells, where the virus uses its fusion (F) and attachment (G) proteins to enter cells and form syncytia (fused cells). This leads to inflammation, mucus production, airway obstruction, and impaired gas exchange due to immune responses involving cytokines and immune cell infiltration.

Diagnosis of RSV is generally based on clinical presentation and can be confirmed using laboratory tests such as reverse transcription polymerase chain reaction (RT-PCR) from nasal or throat swabs, which is the most sensitive method. Additional diagnostic tools include pulse oximetry to assess oxygen levels and chest X-rays in severe cases to evaluate lung involvement.

Treatment is mainly supportive, as there is no specific antiviral therapy routinely recommended for most patients. Management includes adequate hydration, antipyretics for fever, oxygen therapy for hypoxia, and in severe cases, hospitalization with ventilatory support. Preventive strategies include good hygiene practices, vaccination in certain populations, and prophylactic monoclonal antibodies for high-risk infants.

"Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory Syncytial Virus (RSV) pipeline landscape is provided which includes the disease overview and Respiratory Syncytial Virus (RSV) treatment guidelines. The assessment part of the report embraces, in depth Respiratory Syncytial Virus (RSV) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence
Respiratory Syncytial Virus (RSV) R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory syncytial virus (RSV).

Respiratory Syncytial Virus (RSV) Emerging Drugs Chapters

This segment of the Respiratory Syncytial Virus (RSV) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Respiratory Syncytial Virus (RSV) Emerging Drugs

• Deuremidevir Hydrobromide: Simcere Pharmaceutical Group

Deuremidevir Hydrobromide (VV116) is an orally administered small-molecule antiviral drug developed by Vigonvita Life Sciences in collaboration with Simcere Pharmaceutical Group, designed for the treatment of viral infections including Respiratory Syncytial Virus (RSV). The drug is a nucleoside analog with broad-spectrum antiviral activity, and its mechanism of action involves inhibition of viral RNA-dependent RNA polymerase (RdRp), thereby blocking viral RNA replication and preventing the spread of infection. It is being developed specifically for the treatment of RSV infection, particularly in infants and young children who are at high risk of severe disease. The drug has received a Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for RSV infection. Deuremidevir Hydrobromide has progressed from earlier studies into advanced development, with Phase 2 completed and currently ongoing Phase III clinical trials for RSV infection.

• S-337395: Shionogi

S-337395 is a novel, orally administered small-molecule antiviral drug candidate being jointly developed by Shionogi and UBE Corporation for the treatment of Respiratory Syncytial Virus (RSV) infection. The drug is designed as an RNA-dependent RNA polymerase (L protein) inhibitor, meaning it blocks the activity of the RSV L protein, which is essential for viral genome transcription and replication, thereby inhibiting viral proliferation inside infected cells rather than preventing viral entry. It is being developed for the treatment of RSV infections, particularly addressing the unmet need for effective antiviral therapies in infants, elderly, and high-risk populations. S-337395 has received Fast Track designation from the U.S. Food and Drug Administration (FDA), highlighting its potential to address a serious condition with unmet medical need. The drug has shown positive results in Phase II clinical trials, demonstrating significant reduction in viral load, and it is currently in ongoing Phase II clinical development for RSV.

• SCTV02: Sinocelltech Ltd.

SCTV02 is a recombinant protein-based vaccine candidate developed by Sinocelltech Ltd. for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine is designed using a stabilized prefusion RSV F (fusion) protein, which is the key antigen responsible for inducing neutralizing antibodies, and its mechanism of action involves stimulating strong humoral immune responses to prevent viral entry into host cells by targeting the RSV F protein. SCTV02 is being developed for the prophylactic prevention of RSV infection, particularly in vulnerable populations such as infants, elderly individuals, and those at high risk of severe disease. SCTV02 has progressed into clinical-stage development and is currently in Phase I/II clinical trials.

• EuRSV: Eubiologics

EuRSV is a recombinant protein-based RSV vaccine candidate developed by EuBiologics for the prevention of Respiratory Syncytial Virus (RSV) infection, particularly targeting high-risk populations such as infants, elderly, and immunocompromised individuals. The vaccine uses a liposome nanoparticle-based platform incorporating RSV antigens (notably the F protein) combined with immune-enhancing adjuvants such as MPLA (TLR4 agonist) and CoPoP technology, which enhances antigen presentation and stimulates both humoral and cellular immune responses. It is being developed specifically for prophylactic use (prevention) against RSV infection rather than treatment. EuRSV is in early-stage clinical development, currently in Phase I clinical trials.

Further product details are provided in the report……..

Respiratory Syncytial Virus (RSV): Therapeutic Assessment

This segment of the report provides insights about the different Respiratory Syncytial Virus (RSV) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Respiratory Syncytial Virus (RSV)

There are approx. 50+ key companies which are developing the therapies Respiratory-syncytial-virus-rsv. The companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. Phase III include, Simcere Pharmaceutical Group, and others.

Phases

The report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Respiratory Syncytial Virus (RSV): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory Syncytial Virus (RSV) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory Syncytial Virus (RSV) drugs.

Respiratory Syncytial Virus (RSV) Report Insights

• Respiratory Syncytial Virus (RSV) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Respiratory Syncytial Virus (RSV) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Respiratory Syncytial Virus (RSV) drugs?
• How many Respiratory Syncytial Virus (RSV) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory Syncytial Virus (RSV)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Respiratory Syncytial Virus (RSV) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Respiratory Syncytial Virus (RSV) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Shionogi
• Zhuhai Trinomab Pharmaceutical Co., Ltd.
• Blue Lake Biotechnology Inc.
• Ark Biosciences
• EuBiologics Co.,Ltd
• Simcere Pharmaceutical Group
• Guangzhou Patronus Biotech Co., Ltd.
• Shenzhen Shenxin Biotechnology Co., Ltd
• Sinocelltech Ltd.
• Enanta Pharmaceuticals, Inc
• MAXVAX Biotechnology Limited Liability Company
• Shanghai Institute Of Biological Products
• PEACHES BIOTECH
• Clover Biopharmaceuticals USA, LLC
• Pulmotect, Inc.
• Synairgen Research Ltd.

Key Products

• S-337395
• TNM001
• PIV5-vectored RSV Vaccine (BLB-201)
• AK0529
• EuRSV
• Deuremidevir Hydrobromide
• LYB005
• IN006 Bivalent mRNA Vaccine
• SCTV02
• Zelicapavir
• Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
• SIBP-A16 injection
• PRS CK STORM
• SCB-1019T
• PUL-042
• SNG001

This product will be delivered within 1-3 business days.